
TVRD Stock Forecast & Price Target
TVRD Analyst Ratings
Bulls say
Tvardi Therapeutics is driven by their innovative approach to developing oral, small molecules that target STAT3, a key protein in inflammatory and fibrotic diseases. With promising results from their Phase 1 trials for liver cancer and ongoing studies for other diseases, the company has potential to make a significant impact in the biopharmaceutical industry. However, it is important to closely monitor the progress of their clinical trials as any delays or setbacks could greatly affect the company's future success.
Bears say
Tvardi Therapeutics is a clinical-stage biopharmaceutical company with a negative outlook due to recent setbacks in their clinical trials. The company's lead program, TTI-101, is currently in Phase 2 clinical development for hepatocellular carcinoma (HCC), but topline results are not expected until 2H26. In addition, the company encountered a meaningful clinical setback when their Phase 2 REVERT trial for idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint in October 2025. Although the company has a potentially promising next-generation compound, TTI-109, in development, it is currently undervalued as TTI-101 remains the primary value driver in their pipeline. The company also faces competition from existing therapies and has experienced high gastrointestinal (GI) discontinuation rates in their trials, which could hinder their success in the market.
This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TVRD Analyst Forecast & Price Prediction
Start investing in TVRD
Order type
Buy in
Order amount
Est. shares
0 shares